Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)

Sponsor
Klinikum Ludwigshafen
Study ID
NCT00562406
Status
Completed

Conditions

  • Macular Edema

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab — DRUG
    intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
  • Laser photocoagulation — PROCEDURE
    laser photocoagulation to the retina at the area of edema

Study Details

The primary objective of this pilot study is to compare the functional and anatomic outcomes of chronic macular edema secondary to branch retinal vein occlusion (BRVO) treated with argon laser photocoagulation versus intravitreal ranibizumab (Lucentis®) injection versus a combination of both.

Key Dates

First listed
Nov 22, 2007
Start date
Nov 30, 2007
Status verified
Jul 2011
Primary completion
Sep 30, 2010
Completion
Sep 30, 2010

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 1
    laser photocoagulation to the retina at the area of edema
  • Experimental: 2
    intravitreal injection of ranibizumab
  • Experimental: 3
    laser photocoagulation to the retina at the area of edema and intravitreal injection of ranibizumab

Primary Outcome Measure

Changes in best spectacle-corrected visual acuity (BSCVA) [ Time Frame: from baseline to month 6 ]

Related Studies